Benzinga · Aug 26, 2026
HC Wainwright & Co. Reiterates Buy on Phio Pharmaceuticals, Maintains $14 Price Target
HC Wainwright & Co. analyst Matthew Keller reiterates Phio Pharmaceuticals (NASDAQ:PHIO) with a Buy and maintains $14 price target.
PH
NASDAQ · PHIO
Phio Pharmaceuticals Corp.
Healthcare · Biotechnology
$0.90
Up+$0.02 (+2.61%)
Updated Nov 4, 2026, 10:38 AM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 12.38M
- P/E ratio
- -7.91
- Dividend yield
- 0.00%
- 52-week range
- $0.84 – $1.35
- Volume
- 33.7K
- Avg. volume
- 2.91M
Price performance · PHIO
PHIO price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
PHIO closed at $0.90 after 21 trading sessions, down 9.19% for the selected period.
- Last close
- $0.90
- Period change
- -9.19%
- Period low
- $0.85
- Period high
- $1.00
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $0.87 | $0.9197 | $0.87 | $0.903 | 33.7K |
| Nov 2, 2026 | $0.8687 | $0.8999 | $0.86 | $0.88 | 29.82K |
| Oct 30, 2026 | $0.86 | $0.8767 | $0.85 | $0.86 | 66.66K |
| Oct 29, 2026 | $0.88 | $0.9148 | $0.8626 | $0.8626 | 26.72K |
| Oct 28, 2026 | $0.8912 | $0.9168 | $0.85 | $0.9168 | 12.5K |
| Oct 27, 2026 | $0.869 | $0.9199 | $0.85 | $0.8912 | 71K |
| Oct 26, 2026 | $0.8826 | $0.8976 | $0.8502 | $0.8502 | 43.07K |
| Oct 23, 2026 | $0.859 | $0.8999 | $0.851 | $0.8524 | 30.73K |
| Oct 22, 2026 | $0.895 | $0.915 | $0.87 | $0.8725 | 53.62K |
| Oct 21, 2026 | $0.908 | $0.92 | $0.8634 | $0.8949 | 100.35K |
| Oct 20, 2026 | $0.859 | $0.9099 | $0.859 | $0.8921 | 60.64K |
| Oct 19, 2026 | $0.87 | $0.89 | $0.8506 | $0.8689 | 90.75K |
| Oct 16, 2026 | $0.9101 | $0.9425 | $0.8707 | $0.8711 | 91.14K |
| Oct 15, 2026 | $0.90 | $0.9801 | $0.90 | $0.9258 | 135.78K |
| Oct 14, 2026 | $0.91 | $0.9499 | $0.89 | $0.9496 | 132.24K |
| Oct 13, 2026 | $0.96 | $0.96 | $0.92 | $0.9345 | 69.6K |
| Oct 12, 2026 | $0.9853 | $0.9853 | $0.9104 | $0.922 | 46.28K |
| Oct 9, 2026 | $0.97 | $0.9999 | $0.97 | $0.9788 | 43.35K |
| Oct 8, 2026 | $0.97 | $0.9924 | $0.9695 | $0.9731 | 66.26K |
| Oct 7, 2026 | $0.9944 | $1.02 | $0.9701 | $0.9995 | 92.96K |
| Oct 6, 2026 | $1.00 | $1.02 | $0.971 | $0.9944 | 131.77K |
Latest PHIO news
The latest Smart Investors Daily articles mentioning PHIO.
Stock researchCompany · Overview
Company
Market Activity
Research & News
PHIO research
Overview
Company profile and research snapshot.
Company profile
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 26, 2026 | HC Wainwright & Co. | Buy | — |
| Feb 10, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 15, 2025 | HC Wainwright & Co. | Buy | — |
| Jun 25, 2025 | HC Wainwright & Co. | Buy | — |
| Apr 8, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Mar 5, 2026
Phio Pharma Q4 EPS $(0.15) Beats $(0.41) Estimate
Yahoo · Feb 23, 2026
Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company
Phase 1b Trial Reported Approximately 65% Pathological Response in cSCC, Including Complete Responses at Maximum Dose, With No Serious Adverse Events FDA Engagement Targeted for Q2 2026; Cash Runway Extended Into First Half of 2027 NEW YORK, NY - Feb...
Yahoo · Feb 19, 2026
Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894
Leadership Enhancements Position Company for Upcoming Regulatory Engagement and Clinical MilestonesNew Appointments Reinforce Operational Readiness Across Finance, Regulatory Affairs and Program LeadershipKing of Prussia, Pennsylvania--(Newsfile Corp. - February 19, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals Corp....
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
